Posiplduo Sustained-release Tablet 10/500 mg
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donghwa Pharmaceutical Co., Ltd.
MFDS item code 202301899 · Approved 2023.06.21
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is prescribed to assist adults with Type 2 diabetes in controlling their blood sugar levels along with dietary and exercise regimens. In particular, it effectively manages blood sugar levels through combination therapy using dapagliflozin and metformin. Additionally, it may help those whose blood sugar is not adequately controlled and who have cardiovascular diseases or risk factors; further information may be needed from a healthcare professional regarding these aspects. Overall, this medication is used to improve blood sugar control.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse effects of metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the patient's existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering drugs. Since any change may lead to changes in glycemic control, any change in treatment of patients with type 2 diabetes should be made under careful monitoring. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Metformin is excreted through the kidneys, and renal function is more likely to be reduced in older adults; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
This medication contains two active ingredients and is used for diabetes treatment. There is a very rare possibility of a serious metabolic complication called lactic acidosis occurring when taking this medication, so caution is necessary. Lactic acidosis can be life-threatening, and if symptoms appear, medical consultation should be sought immediately. Additionally, when used with insulin or sulfonylureas, hypoglycemia may occur, so blood sugar levels should be monitored closely. This medication should not be administered to patients with severely impaired kidney function, who are dehydrated, or have certain diseases such as severe infections, heart failure, or acute myocardial infarction. There may be a need to discontinue this medication for a period before and after tests or surgeries due to the risk of changes in kidney function and lactic acidosis. It is safer not to use this medication in pregnant or breastfeeding women and to consult a doctor before taking it. This medication should be administered with caution in patients at risk of decreased fluid volume or hypotension, especially in older adults or those with impaired kidney function, who should receive regular kidney function tests. During treatment, genital infections or urinary tract infections may occur, and if symptoms appear, immediate treatment is needed. Vitamin B12 levels may decrease; thus, regular blood tests are necessary for monitoring when this medication is taken over a long period. Excessive alcohol consumption should be avoided, and blood sugar control status should be checked periodically during treatment. This medication may interact with other drugs, so if you are currently taking other medications, you must inform your healthcare provider. Dizziness or hypotension may occur during treatment, so caution is needed when driving or operating dangerous machinery. Finally, keep this medication out of reach of children, and store it in its original container to maintain its quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture exposure. It is also recommended to store it at room temperature between 1 degree Celsius and 30 degrees Celsius, away from extremely hot or cold environments.
Pink, oval-shaped, double-convex, sustained-release film-coated tablet
30 tablets/bottle, 200 tablets/bottle, 30 tablets/box [(6 tablets/PTP)*5]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donghwa Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Il-Yang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.